Scientists at
Philips Research are developing a localized drug delivery system based on
ultrasound and microbubbles that are partially filled with cancer drugs. NEW
YORK, US - Philips is developing an ultrasound-based drug delivery technology
that is designed to increase the effectiveness and reduce the side effects of
chemotherapy treatment for certain types of cancer. The system proposes the use
of drug-loaded microbubbles, no larger than red blood cells, that can be
injected into the patient’s bloodstream, tracked via ultrasound imaging, and
then ruptured by a focused ultrasound pulse to release their drug payload when
they reach the desired spot. Because the drugs would only be released at the
site of the diseased tissue, the patient’s total body exposure to them could be
limited. For certain types of treatment – for example, chemotherapy for breast
cancer – this could help to reduce unpleasant side effects.
The use of
microbubbles in conjunction with medical ultrasound imaging is not new.
However, at the moment in clinical practice, microbubbles are only used as
contrast agents for example to highlight blood in the ultrasound images – an
application that relies on the fact that microbubbles reflect ultrasound much
better than blood or soft tissue.
The drug delivery technology being developed by scientists at Philips Research continues to utilize the contrast-enhancing capabilities of microbubbles to help ultrasound operators to locate tumors – based on their density and the fact that tumors typically grow a recognizable network of small blood vessels around themselves. What’s new is that it then shatters the shells of the microbubbles in these blood vessels using a focused high-energy ultrasound pulse. As a result, the drugs contained in the microbubbles are released directly inside the tumor.
Philips is working
with several academic partners, including the University of Virginia (USA) and
the University of Muenster (Germany), to refine the technology. Clinical
institutions, such as The Methodist Hospital in Houston (USA), are also
actively researching this new and exciting field of ultrasound mediated drug
delivery.
“More and more,
patients are demanding treatment options that allow them to maintain their
quality of life during the treatment regime, without sacrificing treatment
efficacy,” comments King Li, MD, Chair of the Department of Radiology at the
Methodist Hospital in Houston (USA) and Professor of Radiology, Weill Cornell
Medical College (USA). ”The non-invasive nature of ultrasound mediated delivery
is a step in this direction. Work at our and other institutions using
ultrasound for drug delivery and treatment guidance has shown the potential of
this technology in pre-clinical studies.”
No comments:
Post a Comment